Novavax (NVAX) Misses Q2 EPS by $12.03, Cuts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $10.45 +7.95%
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27 billion.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot Guidance, Trading HaltsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
